BAM
IRWD icon

Belpointe Asset Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Belpointe Asset Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-105
Closed -$1.1K – 1943
2023
Q1 		$1.1K Buy
+105
New +$1.18K ﹤0.01% 3455

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Belpointe Asset Management's IRWD Position: Q2 2023 in Review

Belpointe Asset Management sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2023, closing a stake of 105 shares — an estimated $1.1K sold.

Belpointe Asset Management first reported a position in IRWD in Q1 2023 and held it in 1 quarter. The position peaked at $1.1K in Q1 2023. 252 funds tracked by Wall St. Rank hold IRWD as of Q2 2023.

  • Belpointe Asset Management reported no remaining Ironwood Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 105 Ironwood Pharmaceuticals shares in Q2 2023, an estimated $1.1K.
  • Belpointe Asset Management first reported a position in Ironwood Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Belpointe Asset Management's Ironwood Pharmaceuticals position peaked at $1.1K in Q1 2023.
  • 252 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.